As Daiichi Sankyo Takes Over Ranbaxy Reins, Japan’s Nippon Chemiphar May Exit Joint Venture
This article was originally published in The Pink Sheet Daily
Executive Summary
Ranbaxy owns half of Nippon Chemiphar subsidiary Nihon, with which it had planned to be influential in the Japanese generics market.
You may also be interested in...
Top Guns From Daiichi Sankyo Take Positions on Ranbaxy Board
MUMBAI - Japanese drug maker Daiichi Sankyo has reorganized the board of directors of Ranbaxy, a company in which it acquired 63.92 percent equity for an investment of $4.5 billion. Ranbaxy CEO and Managing Director Malvinder Mohan Singh will assume an additional role as chairman in the newly structured board
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.